Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/000992289703600815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of a transapical edge-to-edge repair system in secondary mitral regurgitation.
J Invasive Cardiol
January 2025
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University; NHC Key Laboratory of Ischemic Heart Diseases; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences; National Clinical Research Center for Interventional Medicine, Shanghai, China.
Objectives: The ValveClamp system (Hanyu Medical Technology) is a novel transcatheter edge-to-edge repair (TEER) system designed for ease of operation; however, there is a lack of data on its application in secondary mitral regurgitation (SMR). The authors report the mid-term outcomes of TEER using the ValveClamp system in SMR.
Methods: The study prospectively analyzed consecutive severe SMR patients who underwent transapical ValveClamp implantation at 10 Chinese centers.
Psychological symptoms, quality of life and dyadic relations in family members of intensive care survivors: a multicentre, prospective longitudinal cohort study.
Ann Intensive Care
January 2025
School of Medicine and Psychology, Australian National University, Canberra, Australia.
Background: There is scarce literature evaluating long term psychological or Quality of Life (QoL) outcomes in family members of ICU survivors, who have not experienced invasive ventilation. The objective was to compare long-term psychological symptoms and QoL outcomes in family members of intubated versus non-intubated ICU survivors and to evaluate dyadic relationships between paired family members and survivors.
Methods: Prospective, multicentre cohort study among four medical-surgical ICUs in Australia.
Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
Int Ophthalmol
January 2025
Chairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Purpose: This study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).
Methods: A 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks.
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.
Breast Cancer Res Treat
January 2025
Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Waima Road 114, Jinping District, Shantou, 515041, China.
Purpose: Precise tumor excision is important in breast-conserving surgery (BCS). This study explores the safety and accuracy of fluorescence image-guided BCS (FIGS) using a lidocaine mucilage-ICG compound (L-ICG).
Methods: 54 patients who underwent BCS from August 2020 to September 2023 were enrolled.
Effects of ranibizumab on microvasculature, oxidative stress and recurrence in primary pterygium surgery.
Int Ophthalmol
January 2025
Department of Ophthalmology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150, Kubang Kerian, Kelantan, Malaysia.
Purpose: To evaluate the effects of pre-operative ranibizumab injection on microvascular density (MVD), 8-hydroxyguanosine (8-OHdG) and recurrence after surgical excision of primary pterygium.
Method: This was a prospective cohort interventional study involving 52 patients with primary pterygium divided equally into control and intervention groups. The intervention group received 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!